Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Queensland Health
Federal Trade Commission
Merck
Cantor Fitzgerald

Generated: September 15, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,623,883

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,623,883 protect, and when does it expire?

Patent 8,623,883 protects VIZIMPRO and is included in one NDA.

This patent has fifty patent family members in forty-two countries.

Summary for Patent: 8,623,883
Title:4-phenylamino-quinazolin-6-yl-amides
Abstract: This invention provides quinazoline compounds of the formula: ##STR00001## wherein: R.sub.1 is halo; R.sub.2 is H or halo; R.sub.3 is a) C.sub.1-C.sub.3 alkyl, optionally substituted by halo; or b) --(CH.sub.2).sub.n-morpholino, --(CH.sub.2).sub.n-piperidine, --(CH.sub.2).sub.n-piperazine, --(CH.sub.2).sub.n-piperazine-N(C.sub.1-C.sub.3 alkyl), --(CH.sub.2).sub.n-pyrrolidine, or --(CH.sub.2).sub.n-imidazole; n is 1 to 4; R.sub.4 is --(CH.sub.2).sub.m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C.sub.1-C.sub.3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH.sub.2, NH(C.sub.1-C.sub.3 alkyl) or N(C.sub.1-C.sub.3 alkyl).sub.2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.
Inventor(s): Fakhoury; Stephen Alan (Fishers, IN), Lee; Helen Tsenwhei (Ann Arbor, MI), Reed; Jessica Elizabeth (Ann Arbor, MI), Schlosser; Kevin Matthew (North Wales, PA), Sexton; Karen Elaine (Kent, GB), Tecle; Haile (Ann Arbor, MI), Winters; Roy Thomas (Pinckney, MI)
Assignee: Warner-Lambert Company LLC (Morris Plains, NJ)
Application Number:13/914,410
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 8,623,883

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-001 Sep 27, 2018 RX Yes No ➤ Sign Up ➤ Sign Up FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST ➤ Sign Up
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-002 Sep 27, 2018 RX Yes No ➤ Sign Up ➤ Sign Up FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST ➤ Sign Up
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-003 Sep 27, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Moodys
Julphar
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.